GO
Loading...

Life Sciences

More

  • GSK sees first Ebola vaccine doses ready late this year Wednesday, 22 Oct 2014 | 8:08 AM ET

    LONDON, Oct 22- GlaxoSmithKline expects to have the first doses of its Ebola vaccine ready late this year and is looking to work with the rest of the pharmaceutical industry to scale up production. "I fully anticipate that the initial supply should be available before the year end," Chief Executive Andrew Witty told reporters on Wednesday after reporting...

  • Johnson & Johnson plans Ebola vaccine testing Wednesday, 22 Oct 2014 | 7:42 AM ET

    NEW BRUNSWICK, N.J.— Johnson& Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus. Johnson& Johnson also plans to test whether its vaccine protects against the version causing the outbreak, which has killed more than 4,500 people. Johnson& Johnson is developing the vaccine...

  • *J&J says has discussed collaboration with GlaxoSmithKline. Johnson& Johnson said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain's GlaxoSmithKline, which is working on a rival vaccine. The World Health Organization hopes that tens of thousands of people in...

  • J&J, GSK ready to collaborate on Ebola vaccine work Wednesday, 22 Oct 2014 | 6:11 AM ET

    LONDON, Oct 22- Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson& Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration. J&J, which aims to have at least 1 million doses of its two-step vaccine available next year, said on Wednesday that vaccine makers would...

  • LONDON, Oct 22- Johnson& Johnson is accelerating work on its experimental Ebola vaccine and said on Wednesday that it aims to have 1 million doses ready in 2015, of which 250,000 are expected to be available by May. There is currently no proven vaccine against the deadly disease but several companies are racing to develop products and clinical tests on two- from...

  • Oct 22- Johnson& Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

  • Cubist beats Street 3Q forecasts Tuesday, 21 Oct 2014 | 4:27 PM ET

    LEXINGTON, Mass. _ Cubist Pharmaceuticals Inc. on Tuesday reported third-quarter net income of $22.8 million. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 6 cents per share. Analysts expected $302.5 million, according to Zacks.

  • WHO: Ebola vaccine trials in W. Africa in January Tuesday, 21 Oct 2014 | 7:19 AM ET

    GENEVA— Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday. The Ebola outbreak in West Africa has already killed over 4,500 people, mostly in Liberia, Guinea and Sierra Leone, since it emerged 10...

  • SYDNEY, Oct 17- Australian biotech firm CSL Ltd, the world's second-biggest blood products maker, said on Friday it's working on a plasma product to treat Ebola following a request from the Bill& Melinda Gates Foundation, part of a growing commercial response to the deadly outbreak. Along with CSL, Sydney- listed protective products maker Ansell Ltd, the world's...

  • SYDNEY, Oct 17- Australian biotech firm CSL Ltd, the world's second-biggest blood products maker, said on Friday it's working on a plasma product to treat Ebola following a request from the Bill& Melinda Gates Foundation, part of a growing commercial response to the deadly outbreak. Along with CSL, Sydney- listed protective products maker Ansell Ltd, the world's...

  • Canadian Ebola vaccine begins testing Monday, 13 Oct 2014 | 11:40 AM ET

    TORONTO— Human testing of an experimental Canadian-made Ebola vaccine began Monday, with federal officials saying the drug could be shipped to West Africa within months if it proves successful. Health Minister Rona Ambrose said the launch of the vaccine's first clinical trial marks a promising step in the global campaign to contain the virus, which the World...

  • NEA, known for backing companies such as Workday Inc, Salesforce.com Inc and Gilt Groupe, is one of the world's top venture firms, with its latest fund totalling $2.6 billion. Health science is one area where women venture capitalists appear to be making serious gains, with some of the most accomplished health investors, including Beth Seidenberg of Kleiner...

  • Oct 6- After nearly a week in hospital, the first Ebola patient diagnosed in the United States began to receive an experimental therapy initially developed to treat other viral diseases, according to the Dallas hospital where he lies in critical condition. On Monday, however, a spokeswoman for Texas Health Presbyterian Hospital said Duncan began receiving a...

  • While Lilly's shares hardly budged on the news, the ADRs of Israel- based XTL Biopharmaceuticals Inc, which is developing its own lupus treatment, nearly tripled to $5.00. About 1.5 million people in the United States are estimated to suffer from lupus, according to the U.S. Centers of Disease Control and Prevention. The U.S. Food and Drug Administration approved...

  • Oct 1- An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday. The LDL reductions seen with the once-daily ETC-1002 pill were somewhat less than can be achieved by more powerful statins, such as Pfizer...

  • Oct 1- A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.

  • NEW YORK, Oct. 1- Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

  • Sept 30- Johnson& Johnson said it would buy privately held drug developer Alios BioPharma Inc for $1.75 billion in cash, to access a portfolio of drugs targeting viral infections. Johnson& Johnson said the deal includes Alios's experimental drug for infants with respiratory syncytial virus.

  • MADRID, Sept 28- Merck& Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system suggest the cocktail is promising, though limited patient numbers mean the data is far from conclusive.